Dr. Ahmed Hamdy is an independent Board Director and Clinical Advisor of Andes Biotechnologies. He is a founder of Acerta Pharma, a member of the AstraZeneca Group, and has previously served as the Chief Executive and Medical Officer. Dr Hamdy has +20 years of clinical research experience in pharmaceutical drug development, seven of which were in academic medical research. As a key Executive Leader he has been directly involved in the processes of growing up Acerta Pharma from 3 employees to 120 employees, increase company valuation from $2 million to $4 billion, acquire 2 compounds from big Pharma, and raise +$500 million in capital from investor Communities.

Dr. Hamdy previously served as the Chief Medical Officer for Pharmacyclics (2009-11). In this position, he was responsible for the development of the BTK inhibitor program including transitioning the molecule from pre-clinical stage into Phase I and Phase II. The products overseen by Dr. Hamdy ranges across all clinical development phases (15 Phase I, 17 Phase II, 8 Phase III, and 3 Phase IV trials) and he has a successful track record of delivering numerous INDs and NDAs.

His role as a Leader in the Clinical Development field is a result of the multiple responsibilities and duties he has undertaken in the Pharmaceutical industry:

  • Therapeutic Area Head at Elan Pharmaceuticals (2008-09)
  • General Medicine Therapeutic Area Head at PDL Biopharma (2006-08)
  • Medical Director at Johnson and Johnson/ALZA (2004-06)
  • Senior Principal Scientist at Watson Pharmaceuticals (2000-04)